Colorado BioScience Association Highlights Medtech Disruption

Annual Medical Device Symposium discusses industry growth, innovation and federal policy outlook

DENVER – On Jan. 30, 2018, the Colorado BioScience Association (CBSA) will host more than 80 medtech leaders to discuss industry metrics, shifting business models, M&A trends, FDA reform and the efforts to seek a permanent repeal of the medical device excise tax during the 2018 CBSA Medical Device Symposium. This annual event gives leaders of Colorado’s medical device industry an in-depth look at economic trends and public policy shaping the U.S. sector, which experienced its best year-on-year growth since the 2008 financial crisis.

April Giles, President & CEO of CBSA, says:

“In a changing healthcare landscape, it’s critical for our established and emerging companies to get early insights on the new developments, policies and trends impacting the device sector. We’re proud to bring Colorado CEOs together to share ideas and learn from speakers who monitor and advocate for the medical device industry on a national level.”

Clayton Hall, Vice President of Government Affairs for the Medical Device Manufacturing Association, says:

“Following this week’s two-year suspension of the medical device excise tax, retroactive to January 1, 2018, we remain committed to a full and permanent repeal of the device tax. We’ll talk about the where we think Congress is headed this year, the upcoming elections, and our ongoing work with the FDA and CMS to create a more predictable regulatory and reimbursement climate for medical technology innovation.”

Additionally, speakers and panelists will provide their perspectives on developing and launching new products and the convergence of digital health and medical technology in the state during the symposium, scheduled for Tuesday, January 30th at the Westin Westminster.

Federal policy preview by Clayton Hall, Vice President of Government Affairs for the Medical Device Manufacturing Association

New national data and insights on the medtech sector from Savi Mittal, Senior Manager, EY

Panel discussion: Medtech Product Innovation and Launch Strategies

Panel discussion: The Immersion of Digital Health and Medtech

Sponsors of the symposium include: Snell & Wilmer, lead sponsor. EY and Fitzsimons Redevelopment Authority, supporting sponsors.

The conference will be held on Jan. 30, 2018 from 1-5:00 p.m. at the Westin Westminster – Lakehouse, 10600 Westminster Blvd. Registration is $50 for CBSA members and $100 for non-members.

Connect with CBSA: Twitter @COBioscience, Facebook and LinkedIn

About the Colorado BioScience Association

Colorado BioScience Association champions life science. We serve as the hub of Colorado’s thriving bioscience sector by connecting innovators to funding, infrastructure, research and talent. From promising young companies to established corporations and institutions, we provide opportunities for networking, education and professional development. We grow the bioscience workforce and lead business expansion policies to advance the industry in our state. CBSA represents more than 350 member organizations, including biotechnology, pharmaceutical, medical device, diagnostic, ag bio and mobile digital health companies, research and academic institutions and service providers. Learn more about us at cobioscience.com.

Media Contacts:

Sheliah Reynolds

Primavera Group for Colorado BioScience Association

(720) 289-4739 sheliah@theprimaveragroup.com

Categories: CBSA News